The clinical-stage biopharmaceutical company saw the highest jump in retail interest after reporting positive topline data ...
Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how competitive Abecma will continue to be in the multiple myeloma space given an ...